Skip to main content
Abbott Laboratories (Pakistan) Limited logo

Abbott Laboratories (Pakistan) Limited — Investor Relations & Filings

Ticker · ABOT ISIN · PK0025701019 LEI · 549300BL6LRIQC5XXV35 PSX Manufacturing
Open in API
Filings indexed 185 across all filing types
Latest filing 2026-03-09 Regulatory Filings
Country PK Pakistan
Listing PSX ABOT

About Abbott Laboratories (Pakistan) Limited

https://www.pk.abbott/homepage.html

Abbott Laboratories (Pakistan) Limited manufactures, imports, and markets a diverse portfolio of healthcare products. Its core activities encompass research-based pharmaceuticals, nutritional products, diagnostic solutions, and diabetes care. The company also provides hospital and consumer products, alongside innovative medical devices and molecular diagnostics, contributing to comprehensive human health solutions.

Recent filings

Filing Released Lang Actions
Board Meeting
Regulatory Filings Classification · 79% confidence The document is a notice to the Pakistan Stock Exchange informing investors of a forthcoming Board of Directors meeting and the associated ‘‘close period’’ for share trading. It contains no financial statements, no change in management, no voting results, nor is it proxy material or an annual or interim report. This type of regulatory disclosure (board meeting notice) falls under general regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-03-09 English
Presentation of Corporate Briefing Session 2025
Annual Report Classification · 95% confidence The document is a detailed corporate briefing session dated December 30, 2025, containing extensive financial data including full-year 2024 financial results and 9-month 2025 financial results. It includes comprehensive revenue analysis, profit margins, segment-wise financial performance, and a statement of financial position as of September 30, 2025. The content is substantive and includes actual financial statements and analysis rather than just summary or announcement. The presence of detailed financial results for a full fiscal year (2024) and interim period (9M FY2025) suggests this is a comprehensive financial report. Given the detailed financial data and analysis for a full fiscal year, this document aligns best with an Annual Report (10-K) or an Interim/Quarterly Report (IR). However, since it includes full-year 2024 results and also 9M 2025 results, it is more consistent with an Annual Report that also provides interim updates. The document is too detailed and lengthy to be a simple earnings release or investor presentation. Therefore, the best classification is Annual Report (10-K). 9M 2025
2025-12-29 English
Corporate Briefing Session 2025
Regulatory Filings Classification · 95% confidence The document is a notice informing about a Corporate Briefing Session (CBS) to be held virtually, where the company will brief analysts and investors about its current financial performance for FY2024 and nine months ended September 30, 2025. It includes meeting details and instructions for participants. The document does not contain actual financial data or detailed financial reports but is an announcement of an upcoming presentation or call. Given the nature of the document as an announcement for a briefing session (similar to an investor presentation or earnings call), but since it is only an announcement and not the transcript or presentation itself, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories. The document length is short (1959 characters), supporting that it is an announcement rather than a full report or transcript.
2025-12-26 English
Appointment of Director
Board/Management Information Classification · 92% confidence The document is a formal letter from Abbott Laboratories (Pakistan) Limited to the Pakistan Stock Exchange notifying the appointment of Mr. Brian William Jordan as a director effective November 25, 2025. This is a clear announcement of a change in the company’s board of directors, matching the Board/Management Information category.
2025-11-25 English
Transmission of Quarterly Reports for the Period Ended September 30, 2025
Interim / Quarterly Report Classification · 95% confidence The document consists of un-audited condensed interim financial statements for the nine months and three months ended September 30, 2025, including Directors’ report, financial highlights, future outlook, and a full condensed interim statement of financial position. It contains substantive financial data and is clearly an interim/quarterly report rather than a simple announcement or certification. Therefore, it should be classified as an Interim/Quarterly Report. 9M 2025
2025-10-30 English
Financial Results for the Quarter Ended September 30, 2025
Interim / Quarterly Report Classification · 98% confidence The document is a detailed interim financial report covering the nine months and quarter ended September 30, 2025, including condensed statements of financial position and profit or loss. It contains substantive financial data (revenues, expenses, balance sheet items) typical of a quarterly/interim report rather than a simple announcement or certification. Therefore, it is classified as an Interim / Quarterly Report. 9M 2025
2025-10-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.